A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the ...
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...
The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.
On Wednesday, the U.S. Food and Drug Administration approved a new pain management drug which could change the way healthcare ...
Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, while Intel’s ...
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...
Analyst Michael Yee of Jefferies maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...